Find, compare & contact
Tipapkinogene sovacivec
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Tipapkinogene sovacivec API 1052105-48-2?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Tipapkinogene sovacivec. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Tipapkinogene sovacivec
- Synonyms:
- DNA (synthetic vaccinia virus strain MVA human papillomavirus-targeted) , MVA-HPV-IL2 vaccine , Tipapkinogene sovacivec
- Cas Number:
- 1052105-48-2
- DrugBank number:
- DB06239
- Unique Ingredient Identifier:
- P34L5Y2SR5
General Description:
Tipapkinogene sovacivec is a chemical compound identified by the CAS number 1052105-48-2. It is known for its distinct pharmacological properties and applications.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in cervical dysplasia/cancer, viral infection, and vulvar dysplasia and carcinoma. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Tipapkinogene sovacivec functions by: TG 4001 is based on the modified vaccinia virus Ankara (MVA virus) carrying and expressing HPV16 E6 and E7 genes. The MVA vector is a highly attenuated strain of vaccinia virus that combines an extensive history of safety with the ability to stimulate a strong immune response to antigens. The TG 4001 therapeutic vaccine induces specific immunity by presentation of E6 and E7 antigens to T cells via major histocompatibility complex (MHC) class I and II inducing specific cellular and humoral responses. A second mechanism may be a non-specific activation of the immune system via the vaccinia virus and the interleukin 2 (IL2) adjuvant of the immune response. TG 4001 could have further applications beyond Cervical Intraepithelial Neoplasia (CIN) 2/3 as a single agent in low grade CIN (CIN1) or cervical cancers in combination with existing treatments. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Tipapkinogene sovacivec is a type of Anticancer drugs
Anticancer drugs belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category designed specifically to combat cancer cells. These powerful medications play a crucial role in cancer treatment and are developed to target and destroy cancerous cells, preventing their growth and spread.
Anticancer drugs are classified based on their mode of action and can include various types such as chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormonal therapy drugs. Chemotherapy drugs work by interfering with the cell division process, thereby inhibiting the growth of cancer cells. Targeted therapy drugs, on the other hand, are designed to attack specific molecules or genes involved in cancer growth, minimizing damage to healthy cells. Immunotherapy drugs stimulate the body's immune system to recognize and destroy cancer cells. Hormonal therapy drugs are used in cancers that are hormone-dependent, such as breast or prostate cancer, to block the hormones that fuel cancer cell growth.
These APIs are typically synthesized through complex chemical processes in state-of-the-art manufacturing facilities. Stringent quality control measures ensure the purity, potency, and safety of these drugs. Anticancer APIs undergo rigorous testing and adhere to stringent regulatory guidelines before being approved for clinical use.
Due to their critical role in cancer treatment, anticancer drugs are in high demand worldwide. Researchers and pharmaceutical companies continually strive to develop new and more effective APIs in this category to enhance treatment outcomes and minimize side effects. The ongoing advancements in the field of anticancer drug development offer hope for improved cancer therapies and better patient outcomes.
